1 Y, Z. et al. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, (2020).
2 S, G. & U, V. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma. Current oncology reports 22, 26, (2020).
3 H, S. et al. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical journal of the American Society of Nephrology : CJASN 14, 1692-1700, (2019).
4 AW, H. et al. A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. The oncologist 25, 121-e213, (2020).
5 JE, S. et al. Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research 26, 545-551, (2020).
6 L, F. et al. Mechanisms of resistance to mTOR inhibitors. Critical reviews in oncology/hematology 147, 102886, (2020).
7 RA, F. et al. Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, (2020).
8 C, D. et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Molecular therapy : the journal of the American Society of Gene Therapy 22, 18-27, (2014).
9 S, C. et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. Journal for immunotherapy of cancer 7, 305, (2019).
10 G, L. et al. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 48, 371-384, (2018).
11 G, W. et al. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway. Molecular cancer 18, 15, (2019).
12 J, S. et al. Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 48, 2549-2562, (2018).
13 MJ, H. et al. HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. Cancer letters 472, 50-58, (2020).
14 X, P., X, W. & H, L. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. International journal of biological macromolecules 118, 24-30, (2018).
15 D, H. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature immunology 19, 1112-1125, (2018).
16 H, Z. et al. Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression. Cell & bioscience 9, 81, (2019).
17 J, E. et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. American journal of cancer research 5, 2799-2807, (2015).
18 H, Z., C, L. & G, Z. MCM3AP-AS1LncRNA Regulates Epidermal Growth Factor Receptor and Autophagy to Promote Hepatocellular Carcinoma Metastasis by Interacting with. DNA and cell biology 38, 857-864, (2019).
19 DJ, C. et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 179, 964-983.e931, (2019).
20 L, P. et al. EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers 12, (2020).
21 T, T. et al. Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. International journal of clinical oncology, (2020).
22 T, W. et al. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer discovery 8, 1142-1155, (2018).
23 B, B. et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta oncologica (Stockholm, Sweden) 57, 498-508, (2018).
24 L, Q. et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European urology 74, 756-763, (2018).
25 W, Z. et al. A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. Molecular cancer 18, 81, (2019).
26 S, K. et al. Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Molecular carcinogenesis 58, 544-553, (2019).
27 W, W. et al. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Molecular cancer 19, 18, (2020).
28 C, W. et al. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. Journal of cellular biochemistry 120, 14916-14927, (2019).
29 M, Z. et al. An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. Molecular neurobiology 55, 3684-3697, (2018).